SCHEMBL3571739

SCHEMBL3571739

Cn1c(=O)c(-c2ccccc2)cc2c3cc(C(=O)NN)ccc3n(C)c21

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.43
▸ EGLN1 Q9GZT9 1/20 0.42
▸ ALDH1A1 P00352 4/20 0.40
▸ MAPT P10636 2/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ SCN9A Q15858 1/20 0.39
▸ RORC P51449 1/20 0.39
▸ NPC1 O15118 3/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ HDAC6 Q9UBN7 2/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ HDAC8 Q9BY41 1/20 0.38
▸ GLA P06280 2/20 0.38
▸ HPGD P15428 2/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ DPP4 P27487 1/20 0.37
▸ PTGDR2 Q9Y5Y4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4765446 0.88 KDM4E (0.42) KDM4EEGLN1ALDH1A1MAPTL3MBTL1
SCHEMBL3569292 0.87 KDM4E (0.58) KDM4EEGLN1ALDH1A1L3MBTL1HSD17B10
SCHEMBL3577537 0.81 MAPT (0.39) KDM4EALDH1A1MAPTL3MBTL1RORC
SCHEMBL4765213 0.79 KDM4E (0.45) KDM4EALDH1A1MAPTHSD17B10HPGD
SCHEMBL3867984 0.78 HSD17B10 (0.46) KDM4EALDH1A1MAPTRORCHSD17B10
SCHEMBL3866299 0.77 HSD17B10 (0.44) KDM4EALDH1A1MAPTL3MBTL1HSD17B10
SCHEMBL3564918 0.76 LOXL2 (0.47) ALDH1A1MAPTL3MBTL1GLAHPGD
SCHEMBL4762397 0.75 KDM4E (0.46) KDM4EALDH1A1MAPTHPGD
SCHEMBL1339005 0.74 ALDH1A1 (0.42) KDM4EALDH1A1MAPTSMN1; SMN2
SCHEMBL1338146 0.74 MEN1 (0.39) KDM4EALDH1A1MAPTNPC1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7812165-B2 6-substituted pyridoindolone derivatives, production and therapeutic use thereof SANOFI-AVENTIS (FR) 2010-10-12 — — US disclosed
EP-1742947-B1 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2008-08-20 — — EP disclosed
US-20070129365-A1 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof SANOFI-AVENTIS (FR) 2007-06-07 — — US disclosed
EP-1742947-A1 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2007-01-17 — — EP disclosed
WO-2005108398-A1 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2005-11-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129365-A1 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof PNPO, CYP2D6, DPYD KDM4E 3074/4885EGLN1 2728/4885ALDH1A1 628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback